DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Theo-24 (Theophylline, Anhydrous) - Summary

 
 



THEO-24 SUMMARY

Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste.

Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.


See all Theo-24 indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Theo-24 (Theophylline)

CDC: Highest Asthma Rates in Healthcare Workers
Source: MedPageToday.com - medical news plus CME for physicians [2016.12.02]
(MedPage Today) -- State-specific analysis showed wide variation in asthma prevalence by industry

Asthma Symptoms, Causes, and Medications
Source: MedicineNet Asthma Complexities Specialty [2016.11.30]
Title: Asthma Symptoms, Causes, and Medications
Category: Slideshows
Created: 11/12/2009 5:02:00 PM
Last Editorial Review: 11/30/2016 12:00:00 AM

Management of Acute Loss of Asthma Control: The Yellow Zone
Source: Medscape Allergy & Clinical Immunology Headlines [2016.11.29]
What are the recommended treatment options for asthma patients in the 'yellow zone'?
Journal for Nurse Practitioners

Australia Storm Triggers 'Unprecedented' Pollen Asthma Attacks
Source: Medscape Allergy & Clinical Immunology Headlines [2016.11.28]
A storm in the Australian city of Melbourne triggered thousands of pollen allergy asthma attacks which killed at least four people and on Thursday was labeled a health emergency of 'unprecedented scale.'
Reuters Health Information

Mouse Allergen in Schools Tied to Worse Asthma for Kids
Source: Medscape Allergy & Clinical Immunology Headlines [2016.11.27]
Mouse allergens in school buildings may be an important environmental factor aggravating kids' asthma, a U.S. study suggests.
Reuters Health Information

more news >>

Published Studies Related to Theo-24 (Theophylline)

The protective effect of theophyline in cisplatin nephrotoxicity. [2014]
Cisplatin is a potent and a major anti-neoplastic drug in the treatment of a broad spectrum of malignancies. However, its clinical use is limited by renal tubular dysfunction that occurs in a significant percent of patients...

Beneficial effects of theophylline infusions in surgical patients with intra-abdominal hypertension. [2011.08]
BACKGROUND: Intra-abdominal hypertension (IAH) can cause high mortality. Recently, we found that IAH was associated with increased serum levels of adenosine and interleukin 10. Our present "hypothesis-generated study" was based on the above mentioned results... CONCLUSIONS: Adenosine receptor antagonism with T following IAH diagnosis resulted in markedly reduced mortality in patients with moderated IAH (<20 mmHg). Theophylline-associated mortality reduction may be related to improved renal perfusion and improved MAP, presumably caused by adenosine receptor blockade. Because this study was not a randomized controlled study, these compelling observations require further multicentric clinical confirmation.

Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults. [2011.07]
OBJECTIVE: To investigate whether a pharmacokinetic drug-drug interaction exists between theophylline (THEO), a CYP1A2 substrate with a narrow therapeutic index, and the concomitant substrate roflumilast (ROF), a novel selective PDE4 inhibitor partially metabolized by CYP1A2... CONCLUSIONS: Neither ROF nor its main metabolite had any impact on the metabolism of the concomitant CYP1A2 substrate THEO in humans. Though co-administration of THEO resulted in a minor increase (28%) in total ROF exposure, no safety or tolerability concerns and no altered total PDE4 inhibition of both ROF and R-NO, were observed.

Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.11]
Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...

Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.09.29]
Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...

more studies >>

Clinical Trials Related to Theo-24 (Theophylline)

Bioavailability of Two Sustained-release Theophylline Products in Healthy Males [Completed]

Study to compare the bioavailability of 350 mg Bronchoretard® - a sustained-release

theophylline (anhydrous) product with respect to the reference product, Theo Dur® 300 mg theophylline anhydrous (sustained-release product) by comparing the rate and extent of absorption of theophylline based on both single and multiple-dose profiles.

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline [Recruiting]
This study is to determine the use of theophylline in patients with NSCLC and advanced solid malignancies and whether treatment with theophylline will help lower or diminish the side effect of diarrhea in patients taking erlotinib. Patients will be enrolled in one of two parts of the study to verify the lowest dose of theophylline that is effective and the highest dose of erlotinib that can be tolerated with theophylline. If this study shows that theophylline is able to inhibit erlotinib induced diarrhea, it will help demonstrate that patients using the tyrosine kinase inhibitor (TKIs), erlotinib, can use it effectively at higher doses without experiencing severe diarrhea.

Evaluation of Metabolic Activity of Liver Metastases by FDG-PET Scanning [Recruiting]
The purpose of this study is to evaluate the effect of primary tumor resection on the metabolic activity of metastases in patients with a colorectal primary tumor and synchronous liver metastases by positron emission tomography (PET) with 2-deoxy-2-fluoro[18F]-D-glucose (FDG-PET) scanning.

Optical Detection of Malignancy During Percutaneous Interventions [Recruiting]
Investigation of application possibilities of optical spectroscopy within the field of oncology. Optical spectroscopy enables the possibility to specifically differentiate between different (human) tissues. The hypothesis is that incorporation of this technique into existing medical devices (e. g. biopsy needle) would enlarge the accuracy and reliability of these devices. The purpose is to improve and speed up the diagnostics and therapy of the malignancies.

Natural History of Noncirrhotic Portal Hypertension [Recruiting]
Background:

- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure

in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH. Objectives:

- To learn more about how NCPH develops over time.

Eligibility:

- People age 12 and older who have NCPH or are at risk for getting it. In the past year,

they cannot have had other types of liver disease that typically result in cirrhosis, liver cancer, or active substance abuse. Design:

- Participants will have 2 screening visits.

- Visit 1: to see if they have or may develop NCPH.

- Medical history

- Physical exam

- Urine and stool studies

- Abdominal ultrasound

- Fibroscan. Sound waves measure liver stiffness.

< TAB> - Visit 2:

- Blood tests

- Abdominal MRI

- Echocardiogram

- Questionnaire

- Liver blood vessel pressure (hepatic venous portal gradient (HVPG)) measurement. This

is done with a small tube inserted in a neck vein.

- They may have a liver biopsy.

- All participants will visit the clinic every 6 months for a history, physical exam, and

blood tests. They will also repeat some of the screening tests yearly.

- Participants with NCPH will also have:

- Upper endoscopy test. A tube inserted in the mouth goes through the esophagus and

stomach.

- At least every 2 years: Esophagogastroduodenoscopy.

- At least every 4 years: testing including HVPG measurements and liver biopsy.

- Participants without NCPH will also have:

- Liver biopsy and HVPG measurements to see if they have NCPH.

- Every 2 years: abdominal MRI and stool studies.

- The study will last indefinitely.

more trials >>


Page last updated: 2016-12-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015